Evidence map›Paper›PMID 37188932›Full record

Trial reportDiabetes, obesity & metabolism2023

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Heidi J Silver, Dianna Olson, Dustin Mayfield, Patricia Wright, Hui Nian, Mona Mashayekhi, John R Koethe, Kevin D Niswender, James M Luther, Nancy J Brown

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 5 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 5 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Heidi J SilverDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0003-2237-4903
Dianna OlsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Dustin MayfieldDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Patricia WrightDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Hui NianDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mona MashayekhiDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0003-0331-2395
John R KoetheDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kevin D NiswenderDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
James M LutherDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Nancy J BrownSchool of Medicine, Yale University, New Haven, Connecticut, USA.
Vanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · USYale University · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002243NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

aimsTo investigate the hypothesis that weight loss with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide alone would lead to a greater reduction in the proportion of fat to lean tissue mass when compared to caloric restriction (CR) alone, as well as when compared to treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, that also enhances GLP-1 activity - to determine the independent effects of each treatment.

methodsA total of 88 adults with obesity and prediabetes were randomized to 14 weeks of intervention with CR (-390 kcal/d), liraglutide (1.8 mg/d), or the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg/d) as a weight-neutral comparator. Changes between groups in appetite and hunger ratings measured via visual analogue scales, dietary intakes, body weight, body composition via dual energy x-ray absorptiometry, and resting energy expenditure via indirect calorimetry were assessed using the Kruskal-Wallis test or Pearson's chi-squared test.

resultsWeight loss ≥5% of baseline body weight occurred in 44% of participants in the CR group, 22% of the liraglutide group and 5% of the sitagliptin group (p = 0.02). The ratio of fat to lean mass decreased by 6.5% in the CR group, 2.2% in the liraglutide group, and 0% in the sitagliptin group (p = 0.02). Visceral fat reduced by 9.5% in the CR group, 4.8% in the liraglutide group, and 0% in the sitagliptin group (p = 0.04). A spontaneous reduction in dietary simple carbohydrates in the CR group was associated with improved homeostatic model assessment of insulin resistance score (HOMA-IR).

conclusionsAlthough both liraglutide and CR are valuable strategies for cardiometabolic risk reduction, CR was associated with greater weight loss and more favourable improvements in body composition than treatment with liraglutide alone. Differences in the response to each of these interventions enables patients to be stratified to the most optimal intervention for their personal risk factors.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsPrediabetic StateAdultAppetiteBody Fat DistributionBody WeightCaloric RestrictionDipeptidyl-Peptidases and Tripeptidyl-PeptidasesEatingGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsLiraglutideObesityDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideSitagliptin Phosphatecaloric restrictiondietglucagon-like peptide-1 (GLP-1) receptor agonistliraglutideobesityprediabetesweight loss

Identifiers

PMID37188932
PMCPMC10544709
OpenAlexW4376642783

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.